{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:33:21Z","timestamp":1792989201161,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.critrevonc.2025.104864","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T06:51:12Z","timestamp":1753253472000},"page":"104864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Towards a new approach in pleural mesothelioma: Perioperative immunotherapy and its implications"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8200-2623","authenticated-orcid":false,"given":"Paolo","family":"Ambrosini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Stanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lo Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Solli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Occhipinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.critrevonc.2025.104864_bib1","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO-24-02239","article-title":"Neoadjuvant nivolumab plus ipilimumab versus chemotherapy in resectable lung cancer","volume":"43","author":"Awad","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"10272","key":"10.1016\/j.critrevonc.2025.104864_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104864_bib3","doi-asserted-by":"crossref","first-page":"11849","DOI":"10.3390\/ijms241411849","article-title":"Neoadjuvant immunotherapy: a promising new standard of care","volume":"24","author":"Boydell","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104864_bib4","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.2012.45.8703","article-title":"Harnessing the immune system for the treatment of non-small-cell lung cancer","volume":"31","author":"Brahmer","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104864_bib5","doi-asserted-by":"crossref","first-page":"924","DOI":"10.21037\/tlcr.2020.03.38","article-title":"Clinical significance of histologic subtyping of malignant pleural mesothelioma","volume":"9","author":"Brcic","year":"2020","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104864_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00392","article-title":"Surgery for mesothelioma after radiation therapy (SMART); a single institution experience","volume":"10","author":"Breen","year":"2020","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104864_bib7","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat. Med"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104864_bib8","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.3390\/cancers15245787","article-title":"Current state-of-the-art therapy for malignant pleural mesothelioma and future options centered on immunotherapy","volume":"15","author":"Cedres","year":"2023","journal-title":"Cancers"},{"issue":"10419","key":"10.1016\/j.critrevonc.2025.104864_bib9","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104864_bib10","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3389\/fonc.2019.01366","article-title":"The immune microenvironment in mesothelioma: mechanisms of resistance to immunotherapy","volume":"9","author":"Chu","year":"2019","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104864_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cllc.2024.02.004","article-title":"Perioperative immunotherapy for non-small cell lung cancer: practical application of emerging data and new challenges","volume":"25","author":"D\u2019Aiello","year":"2024","journal-title":"Clin. Lung Cancer"},{"issue":"10308","key":"10.1016\/j.critrevonc.2025.104864_bib12","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104864_bib13","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104864_bib14","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat. Med"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104864_bib15","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104864_bib16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.jtho.2019.04.029","article-title":"A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute\u2013International Association for the Study of Lung Cancer\u2013Mesothelioma Applied Research Foundation Taskforce","volume":"14","author":"Friedberg","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104864_bib17","first-page":"1","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2025.104864_bib18","article-title":"Prevalence and clinical association of CD276 (B7-H3) expression in pleural mesothelioma: results from the european thoracic platform mesoscape project","volume":"9","author":"Haberecker","year":"2025","journal-title":"JCO Precis Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104864_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003032","article-title":"Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy","volume":"9","author":"Harber","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104864_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.lungcan.2023.03.003","article-title":"TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy","volume":"178","author":"Heged\u00fcs","year":"2023","journal-title":"Lung Cancer"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104864_bib21","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non\u2013small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104864_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.660039","article-title":"Tumor immune microenvironment and genetic alterations in mesothelioma","volume":"11","author":"Hiltbrunner","year":"2021","journal-title":"Front Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104864_bib23","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jtho.2024.03.010","article-title":"Evaluation of major pathologic response and pathologic complete response as surrogate end points for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in NSCLC","volume":"19","author":"Hines","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104864_bib24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.pccm.2024.11.003","article-title":"Neoadjuvant immunotherapy for non-small cell lung cancer: opportunities and challenges","volume":"2","author":"Hu","year":"2024","journal-title":"Chin. Med J. Pulm. Crit. Care Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104864_bib25","first-page":"165","article-title":"The role of regulatory T cells in mesothelioma","volume":"5","author":"Ireland","year":"2012","journal-title":"Cancer Micro"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104864_bib26","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.3390\/jcm13195837","article-title":"Malignant pleural mesothelioma: a comprehensive review","volume":"13","author":"Jain","year":"2024","journal-title":"J. Clin. Med"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104864_bib27","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.3390\/cancers13143637","article-title":"Hyperthermic intrathoracic chemoperfusion for malignant pleural mesothelioma: systematic review and meta-analysis","volume":"13","author":"J\u00e4rvinen","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104864_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1286104","article-title":"Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges","volume":"13","author":"Kalvapudi","year":"2023","journal-title":"Front Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104864_bib29","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","article-title":"Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma","volume":"27","author":"Krug","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104864_bib30","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3390\/cancers16091719","article-title":"The role of surgery in pleural mesothelioma","volume":"16","author":"Lapidot","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104864_bib31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2017.07.010","article-title":"Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: predictive factors and outcomes","volume":"111","author":"Lau","year":"2017","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104864_bib32","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1078-0432.CCR-22-2566","article-title":"A phase II window of opportunity study of neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 blockade for patients with malignant pleural mesothelioma","volume":"29","author":"Lee","year":"2023","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104864_bib33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","article-title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial","volume":"12","author":"Lim","year":"2024","journal-title":"Lancet Respir. Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104864_bib34","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104864_bib35","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.3390\/jcm10112470","article-title":"Molecular Fingerprints of Malignant Pleural Mesothelioma: Not Just a Matter of Genetic Alterations","volume":"10","author":"Lorenzini","year":"2021","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.critrevonc.2025.104864_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107928","article-title":"Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma","volume":"195","author":"Mansfield","year":"2024","journal-title":"Lung Cancer"},{"issue":"6280","key":"10.1016\/j.critrevonc.2025.104864_bib37","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104864_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003288","article-title":"JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma","volume":"9","author":"Miyamoto","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104864_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-78159-y","article-title":"The role of PD-L1 in patients with non-small cell lung cancer receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy: a meta-analysis","volume":"14","author":"Mo","year":"2024","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104864_bib40","doi-asserted-by":"crossref","first-page":"S713","DOI":"10.1016\/j.jtho.2023.09.1376","article-title":"EP14.01-05 Neo-Adjuvant Immunotherapy in Malignant Pleural Mesothelioma: Report on Three Cases Treated in a Single Institution","volume":"18","author":"Novellis","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104864_bib41","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104864_bib42","doi-asserted-by":"crossref","first-page":"S1138","DOI":"10.1016\/j.annonc.2023.09.985","article-title":"2203P Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma","volume":"34","author":"Occhipinti","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104864_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104481","article-title":"Unleashing precision: a review of targeted approaches in pleural mesothelioma","volume":"203","author":"Occhipinti","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104864_bib44","article-title":"Feasibility and safety of neoadjuvant nivolumab and chemotherapy for resectable diffuse pleural mesotheliomas: results of a prospective pilot study","volume":"42","author":"Offin","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104864_bib45","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.cllc.2023.10.010","article-title":"Long-term survival analysis of pleural mesothelioma patients undergoing surgery: brief report from a tertiary referral centre","volume":"25","author":"Orlandi","year":"2024","journal-title":"Clin. Lung Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104864_bib46","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104864_bib47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2012.03.001","article-title":"An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma","volume":"39","author":"Pasello","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.104864_bib48","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8122","article-title":"Phase II study of pembrolizumab in combination with cisplatin or carboplatin and pemetrexed as induction chemoimmunotherapy in resectable epithelioid and biphasic pleural mesothelioma (CHIMERA study)","volume":"43","author":"Pasello","year":"2025","journal-title":"JCO"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104864_bib49","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104864_bib50","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104864_bib51","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol."},{"issue":"30","key":"10.1016\/j.critrevonc.2025.104864_bib52","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/1759-7714.15095","article-title":"En bloc resection of the recurrent pleural mesothelioma and reconstruction of the chest wall after immunotherapy: a case report","volume":"14","author":"Qin","year":"2023","journal-title":"Thorac. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104864_bib53","doi-asserted-by":"crossref","first-page":"2302114","DOI":"10.1183\/13993003.02114-2023","article-title":"A randomised phase II study of extended pleurectomy\/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205","volume":"63","author":"Raskin","year":"2024","journal-title":"Eur. Respir. J."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104864_bib54","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104864_bib55","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","article-title":"Association of High Tumor Mutation Burden in Non\u2013Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels","volume":"8","author":"Ricciuti","year":"2022","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104864_bib56","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-21-1181","article-title":"Phase I\/IIa Trial of BMS-986148, an Anti-mesothelin Antibody\u2013drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors","volume":"28","author":"Rottey","year":"2022","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104864_bib57","doi-asserted-by":"crossref","DOI":"10.1177\/10732748231161466","article-title":"Prognostic role of pathological complete response in early stage epithelial solid tumors","volume":"30","author":"Saltalamacchia","year":"2023","journal-title":"Cancer Control"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104864_bib58","article-title":"Assessing pathologic response in resected lung cancers: current standards, proposal for a novel pathologic response calculator tool, and challenges in practice","volume":"3","author":"Saqi","year":"2022","journal-title":"JTO Clin. Res Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104864_bib59","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104864_bib60","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104864_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.836751","article-title":"Complete pathological response after neoadjuvant chemo-immunotherapy in malignant pleural mesothelioma","volume":"12","author":"Tostes","year":"2022","journal-title":"Front Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104864_bib62","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104864_bib63","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104864_bib64","doi-asserted-by":"crossref","first-page":"S870","DOI":"10.1016\/j.jtho.2021.08.076","article-title":"OA13.01 S1619 a trial of neoadjuvant cisplatin-pemetrexed with atezolizumab in combination and maintenance for resectable pleural mesothelioma","volume":"16","author":"Tsao","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104864_bib65","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.jtho.2024.01.018","article-title":"The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma","volume":"19","author":"Wolf","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104864_bib66","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.14336\/AD.2022.0407","article-title":"Tumor immune microenvironment and immunotherapy in non-small cell lung cancer: update and new challenges","volume":"13","author":"Xing","year":"2022","journal-title":"Aging Dis."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104864_bib67","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.21037\/tlcr-24-195","article-title":"Major pathological response obtained after neoadjuvant chemotherapy combined with dual immunotherapy for malignant pleural mesothelioma: a case report","volume":"13","author":"Zhang","year":"2024","journal-title":"Transl. Lung Cancer Res"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:49:24Z","timestamp":1792986564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825002525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":67,"alternative-id":["S1040842825002525"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104864","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards a new approach in pleural mesothelioma: Perioperative immunotherapy and its implications","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104864","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104864"}}